Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00685945 · ClinicalTrials.gov registry record · NA
Renin-Angiotensin Aldosterone System and Fibrinolysis Interaction in Humans-Specific Aim 3
A NA study, sponsored by Vanderbilt University.
- Completed
- Registry status
- NA
- Development phase
- 24
- Enrollment target
NCT00685945: Completed NA study, sponsored by Vanderbilt University.
NCT00685945 is a NA study that has completed, run by Vanderbilt University. The registered enrollment target is 24 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00685945, a NA study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of the study is to determine if giving isosorbide,a drug that is used to treat chest pain, affects blood vessel release of an anti-clotting factor.
Primary Outcome
Individual net t-PA release at each time point were calculated by the following formula: net release = (Cv-CA) x {FBF x \[101-hematocrit/100\]}, where Cv and CA represent the concentration of t-PA in the brachial vein and artery, respectively.
Interventions
- DRUG Control (bradykinin)
- DRUG L-NMMA + bradykinin
- DRUG Isosorbide + L-NMMA + bradykinin
- DRUG Sildenafil + L-NMMA + bradykinin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2007-12 |
| Est. Completion | 2009-01 |
| Phase | NA |
What the finished NCT00685945 record still lists
NCT00685945 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 4 interventions - of which Control (bradykinin) is the first listed.
NCT00685945 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00685945 about?
NCT00685945 is a clinical study titled "Renin-Angiotensin Aldosterone System and Fibrinolysis Interaction in Humans-Specific Aim 3". The purpose of the study is to determine if giving isosorbide,a drug that is used to treat chest pain, affects blood vessel release of an anti-clotting factor.
What is the current status of trial NCT00685945?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2007-12. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00685945?
The interventions under investigation include: Control (bradykinin) (DRUG), L-NMMA + bradykinin (DRUG), Isosorbide + L-NMMA + bradykinin (DRUG), Sildenafil + L-NMMA + bradykinin (DRUG).
Who is sponsoring clinical trial NCT00685945?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00685945's enrollment target sits among peer trials
24 1736th of 2000 higher than 246 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia